
Kluwer Patent Blog

Yeda v. OCNL, Administrative Law Division of the Council of State (Afdeling Bestuursrechtspraak Raad van State), 27 May 2009

Peter Burgers (Brinkhof) · Wednesday, May 27th, 2009

The Administrative Law Division of the Council of State holds that the District Court has rightfully found that the Patent Office was not obligated to issue a Supplementary Protection Certificate for the medicinal product cetuximab. Article 73 (1) of the Dutch Patents Act 1995 on indirect infringement, does not in all circumstances protect the patentee against the sale or distribution of cetuximab, an essential means regarding the patented combination of cetuximab and irinotecan.


The [full summary](#) of this case has been published on [Kluwer IP Law](#).

To make sure you do not miss out on regular updates from the Kluwer Patent Blog, please subscribe [here](#).

Kluwer IP Law

The **2021 Future Ready Lawyer survey** showed that 81% of the law firms expect to view technology as an important investment in their future ability to thrive. With Kluwer IP Law you can navigate the increasingly global practice of IP law with specialized, local and cross-border information and tools from every preferred location. Are you, as an IP professional, ready for the future?

Learn how [Kluwer IP Law](#) can support you.



Kluwer IP Law

 Wolters Kluwer

This entry was posted on Wednesday, May 27th, 2009 at 6:51 am and is filed under [Case Law](#), [Chemical Engineering](#), [Extent of Protection](#), [Netherlands](#), [Scope of protection](#). You can follow any responses to this entry through the [Comments \(RSS\)](#) feed. Both comments and pings are currently closed.